AroCell AB (publ) (AROC.ST)
SEK 0.49
(-2.18%)
SEK 0.49
(-2.18%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 57.68 Million SEK | 0.51% |
| 2022 | 58.01 Million SEK | 26.75% |
| 2021 | 45.77 Million SEK | 89.8% |
| 2020 | 24.11 Million SEK | 15.9% |
| 2019 | 20.8 Million SEK | 2.56% |
| 2018 | 20.28 Million SEK | 15.98% |
| 2017 | 17.49 Million SEK | 89.54% |
| 2016 | 9.22 Million SEK | 23.3% |
| 2015 | 7.48 Million SEK | 16.77% |
| 2014 | 6.4 Million SEK | 72.34% |
| 2013 | 3.71 Million SEK | 18.82% |
| 2012 | 3.12 Million SEK | -10.69% |
| 2011 | 3.5 Million SEK | 65.47% |
| 2010 | 2.11 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 14.17 Million SEK | -4.93% |
| 2024 Q3 | 13.13 Million SEK | -18.32% |
| 2024 Q2 | 16.08 Million SEK | 13.46% |
| 2023 FY | 58.31 Million SEK | 0.51% |
| 2023 Q3 | 14.04 Million SEK | -5.99% |
| 2023 Q2 | 14.93 Million SEK | 8.5% |
| 2023 Q4 | 14.91 Million SEK | 6.22% |
| 2023 Q1 | 13.76 Million SEK | -24.31% |
| 2022 Q1 | 14.59 Million SEK | -19.09% |
| 2022 Q4 | 18.18 Million SEK | 46.3% |
| 2022 Q3 | 12.43 Million SEK | -6.37% |
| 2022 Q2 | 13.27 Million SEK | -8.99% |
| 2022 FY | 58.01 Million SEK | 26.75% |
| 2021 Q1 | 6.08 Million SEK | 0.88% |
| 2021 Q3 | 14.92 Million SEK | 121.64% |
| 2021 Q4 | 18.03 Million SEK | 20.86% |
| 2021 FY | 45.77 Million SEK | 89.8% |
| 2021 Q2 | 6.73 Million SEK | 10.63% |
| 2020 Q1 | 5.51 Million SEK | -7.23% |
| 2020 Q4 | 6.03 Million SEK | -5.31% |
| 2020 FY | 24.11 Million SEK | 15.9% |
| 2020 Q3 | 6.37 Million SEK | 2.82% |
| 2020 Q2 | 6.19 Million SEK | 12.29% |
| 2019 Q4 | 5.94 Million SEK | 30.65% |
| 2019 Q3 | 4.55 Million SEK | -8.61% |
| 2019 FY | 20.8 Million SEK | 2.56% |
| 2019 Q1 | 5.32 Million SEK | -2.48% |
| 2019 Q2 | 4.98 Million SEK | -6.5% |
| 2018 Q1 | 4.18 Million SEK | -27.41% |
| 2018 Q2 | 5.35 Million SEK | 28.1% |
| 2018 FY | 20.28 Million SEK | 15.98% |
| 2018 Q4 | 5.46 Million SEK | 3.34% |
| 2018 Q3 | 5.28 Million SEK | -1.33% |
| 2017 Q4 | 5.76 Million SEK | 56.64% |
| 2017 FY | 17.49 Million SEK | 89.54% |
| 2017 Q3 | 3.67 Million SEK | -2.47% |
| 2017 Q2 | 3.77 Million SEK | -11.91% |
| 2017 Q1 | 4.28 Million SEK | 67.5% |
| 2016 FY | 9.22 Million SEK | 23.3% |
| 2016 Q1 | 2.84 Million SEK | 73.13% |
| 2016 Q2 | 1.9 Million SEK | -33.08% |
| 2016 Q3 | 2.63 Million SEK | 38.59% |
| 2016 Q4 | 2.55 Million SEK | -3.04% |
| 2015 FY | 7.48 Million SEK | 16.77% |
| 2015 Q2 | 1.64 Million SEK | -31.58% |
| 2015 Q1 | 2.39 Million SEK | -14.96% |
| 2015 Q4 | 1.64 Million SEK | -9.1% |
| 2015 Q3 | 1.8 Million SEK | 10.12% |
| 2014 Q1 | 1.11 Million SEK | -28.68% |
| 2014 Q4 | 2.81 Million SEK | 165.41% |
| 2014 FY | 6.4 Million SEK | 72.34% |
| 2014 Q3 | 1.06 Million SEK | -25.05% |
| 2014 Q2 | 1.41 Million SEK | 27.43% |
| 2013 FY | 3.71 Million SEK | 18.82% |
| 2013 Q1 | 855 Thousand SEK | -16.91% |
| 2013 Q4 | 1.55 Million SEK | 253.54% |
| 2013 Q3 | 441 Thousand SEK | -48.96% |
| 2013 Q2 | 864 Thousand SEK | 1.05% |
| 2012 Q1 | 715 Thousand SEK | -38.31% |
| 2012 Q2 | 873 Thousand SEK | 22.1% |
| 2012 Q4 | 1.02 Million SEK | 94.52% |
| 2012 Q3 | 529 Thousand SEK | -39.4% |
| 2012 FY | 3.12 Million SEK | -10.69% |
| 2011 Q2 | 1.19 Million SEK | 76.89% |
| 2011 Q3 | 478 Thousand SEK | -59.97% |
| 2011 FY | 3.5 Million SEK | 65.47% |
| 2011 Q1 | 675 Thousand SEK | 12.33% |
| 2011 Q4 | 1.15 Million SEK | 142.47% |
| 2010 Q3 | 578 Thousand SEK | 4.9% |
| 2010 Q2 | 551 Thousand SEK | 0.0% |
| 2010 Q4 | 600.91 Thousand SEK | 3.96% |
| 2010 FY | 2.11 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Devyser Diagnostics AB (publ) | 204.6 Million SEK | 71.807% |
| Immunovia AB (publ) | 291.35 Million SEK | 80.202% |
| Prostatype Genomics AB (publ) | 3.22 Million SEK | -1688.589% |
| SenzaGen AB | 49.67 Million SEK | -16.126% |
| Spermosens AB | 10.72 Million SEK | -437.828% |